1.Giske, CG, Monnet, DL, Cars, O, Carmeli, Y; on behalf of ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008;52:813–821.
2.Meyer, E, Schwab, F, Gastmeier, P, Rueden, H, Daschner, FD. Surveillance of antimicrobial use and antimicrobial resistance in German intensive care units (SARI): a summary of the data from 2001 through 2004. Infection 2006;34:303–309.
3.Ferech, M, Coenen, S, Malhotra-Kumar, S, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother 2006;58:401–407.
4.White, RL, Friedrich, LV, Mihm, LB, Bosso, JA. Assessment of the relationship between antimicrobial usage and susceptibility: differences between the hospital and specific patient-care areas. Clin Infect Dis 2000;31:16–23.
5.Vander Stichele, RH, Elseviers, MM, Ferech, M, Blot, S, Goossens, H. Hospital consumption of antibiotics in 15 European countries: results of the ESAC Retrospective Data Collection (1997–2002). J Antimicrob Chemother 2006;58:159–167.
6.Monroe, S, Polk, R. Antimicrobial use and bacterial resistance. Curr Opin Microbiol 2000;3:496–501.
7.Levy, SB. The 2000 Garrod lecture. Factors impacting on the problem of antibiotic resistance. J Antimicrob Chemother 2002;49:25–30.
8.Gaynes, R, Monnet, D. The contribution of antibiotic use on the frequency of antibiotic resistance in hospitals. Ciba Found Symp 1997;207:47–56.
9.Sandiumenge, A, Diaz, E, Rodriguez, A, et al. Impact of diversity of antibiotic use on the development of antimicrobial resistance. /Antimicrob Chemother 2006;57:1197–1204.
10.Austin, DJ, Kristinsson, KG, Anderson, RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 1999;96:1152–1156.
11.Hsueh, PR, Chen, WH, Luh, KT. Relationships between antimicrobial use and antimicrobial resistance in gram-negative bacteria causing nosocomial infections from 1991–2003 at a university hospital in Taiwan. Int J Antimicrob Agents 2005;26:463–472.
12.Frank, U, Kleissle, EM, Daschner, FD, et al. Multicentre study of antimicrobial resistance and antibiotic consumption among 6,780 patients with bloodstream infections. Eur J Clin Microbiol Infect Dis 2006;25:815–817.
13.Mutnick, AH, Rhomberg, PR, Sader, HS, Jones, RN. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999–2001). J Antimicrob Chemother 2004;53:290–296.
14.Neuhauser, MM, Weinstein, RA, Rydman, R, Danziger, LH, Karam, G, Quinn, JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885–888.
15.Martinez, JA, Aguilar, J, Almela, M, et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia. JAntimicrob Chemother 2006;58:1082–1085.
16.Lee, SO, Kim, NJ, Choi, SH, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumatmii: a case-control study. Antimicrob Agents Chemother 2004;48:224–228.
17.Katragkou, A, Kotsiou, M, Antachopoulos, C, et al. Acquisition of imipenem-resistant Acinetobacter baumannii in a pediatric intensive care unit: a case-control study. Intensive Care Med 2006;32:1384–1391.
18.Goossens, H, Ferech, M, Vander Stichele, R, Elseviers, M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365:579–587.
19.Fridkin, SK, Steward, CD, Edwards, JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project 1CARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999;29:245–252.
20.MacDougall, C, Powell, JP, Johnson, CK, Edmond, MB, Polk, RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005;41:435–440.
21.Bassetti, M, Cruciani, M, Righi, E, et al. Antimicrobial use and resistance among gram-negative bacilli in an Italian intensive care unit (ICU). J Chemother 2006;18:261–267'.
22.de With, K, Meyer, E, Steib-Bauert, M, Schwab, F, Daschner, FD, Kern, WV. Antibiotic use in two cohorts of German intensive care units. J Hosp Infect 2006;64:231–237.
23.Monnet, DL. ABC Calc—antibiotic consumption calculator, version 1.9. Copenhagen, Denmark: Statens Serum Institut, 2003.
24.Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 16th informational supplement. Wayne, PA: CLSI, 2006:M100–S16.
25.Hellenic Centre for Infectious Diseases Control (HCIDC) Web page. Available at: http://www.keel.org.gr/en/. Accessed December 31, 2007.
26.Livermore, DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34:634–640.
27.Livermore, DM, Woodford, N. The beta-lactamase threat in Enterobacte-riaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006;14:413–420.
28.Lepper, PM, Grusa, E, Reichl, H, Hogel, J, Trautmann, M. Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002;46:2920–2925.
29.López-Lozano, JM, Monnet, DL, Yague, A, et al. Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: a time series analysis. Int J Antimicrob Agents 2000;14:21–31.
30.Miller, GH, Sabatelli, FJ, Hare, RS, et al. The most frequent aminoglycoside resistance mechanisms—changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis 1997;24:S46–62.
31.Loeffler, JM, Garbino, J, Lew, D, Harbarth, S, Rohner, P. Antibiotic consumption, bacterial resistance and their correlation in a Swiss university hospital and its adult intensive care units. Scand J Infect Dis 2003;35:843–850.
32.Lesch, CA, Itokazu, GS, Danziger, LH, Weinstein, RA. Multi-hospital analysis of antimicrobial usage and resistance trends. Diagn Microbiol Infect Dis 2001;41:149–154.
33.Ena, J, Lopez-Perezagua, MM, Martinez-Peinado, C, Cia-Barrio, MA, Ruiz-Lopez, I. Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones. Diagn Microbiol Infect Dis 1998;30:103–107.